Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

Advertisement

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Top News in Prevention: 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content